Updates in IgA Nephropathy – Part 1 with Dr. Brad Rovin
April 8, 2025 • Kidney Disease Content Hub
Brad Rovin, MD, chief of nephrology at Ohio State University Wexner Medical Center, provides updates on the KDIGO guidelines for IgA nephropathy. The revised guidelines reflect new clinical trials, epidemiologic insights, and the introduction of disease-modifying therapies. Emphasis is placed on reducing proteinuria beyond the previous target of 1 gram per day and preserving glomerular filtration rate. Rovin highlights three classes of approved drugs: gut-targeted steroids, receptor blockers, and complement inhibitors. He anticipates further advances from B cell–targeting agents. He also stresses the importance of patient education, early specialist referral, and overcoming barriers such as drug cost and outdated perceptions.
